{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:14:41Z","timestamp":1791976481112,"version":"4.4.0"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23490712700"],"award-info":[{"award-number":["23490712700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22474042"],"award-info":[{"award-number":["22474042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["W2412035"],"award-info":[{"award-number":["W2412035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.addr.2026.115808","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:39:47Z","timestamp":1770914387000},"page":"115808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Stimuli-activatable protein degraders for targeted cancer therapy: from prodrug design to nanoplatform applications"],"prefix":"10.1016","volume":"232","author":[{"given":"Xingyu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunna","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115808_bb0005","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.molcel.2021.05.004","article-title":"Maintenance of organellar protein homeostasis by ER-associated degradation and related mechanisms","volume":"81","author":"Lemberg","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0010","first-page":"235","article-title":"Extracellular protein homeostasis in neurodegenerative diseases","volume":"19","author":"Wilson","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.addr.2026.115808_bb0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","article-title":"Proteasomal and autophagic degradation systems","volume":"86","author":"Dikic","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.addr.2026.115808_bb0020","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1080\/15548627.2024.2389607","article-title":"Pharmacological inhibition of USP14 delays proteostasis-associated aging in a proteasome-dependent but foxo-independent manner","volume":"20","author":"Lim","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2026.115808_bb0025","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2215-0366(19)30520-6","article-title":"The ubiquitin proteasome system and schizophrenia","volume":"7","author":"Luza","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.addr.2026.115808_bb0030","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.tcb.2023.07.003","article-title":"The ubiquitin-proteasome system links NADPH metabolism to ferroptosis","volume":"33","author":"Yang","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156135","article-title":"Diosmin reduces the stability of snail and cyclin D1 by targeting FAK to inhibit NSCLC progression","volume":"135","author":"Ma","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.addr.2026.115808_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114780","article-title":"Macrophage NRF1 promotes mitochondrial protein turnover via the ubiquitin proteasome system to limit mitochondrial stress and inflammation","volume":"43","author":"Yan","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2026.115808_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114149","article-title":"Thbs1 regulates skeletal muscle mass in a TGF\u03b2-Smad2\/3-ATF4-dependent manner","volume":"43","author":"Vanhoutte","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2026.115808_bb0050","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1080\/15548627.2021.1872189","article-title":"C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels","volume":"17","author":"Beckers","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2026.115808_bb0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tcb.2022.07.005","article-title":"The Cys\/N-degron pathway in the ubiquitin-proteasome system and autophagy","volume":"33","author":"Heo","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature14587","article-title":"Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism","volume":"524","author":"Perera","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-017-0436-9","article-title":"Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment","volume":"10","author":"Yoshida","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0070","article-title":"Tau degradation in Alzheimer's disease: mechanisms and therapeutic opportunities","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.addr.2026.115808_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102584","article-title":"Targeted protein degradation: expanding the technology to facilitate the clearance of neurotoxic proteins in neurodegenerative diseases","volume":"102","author":"Wang","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-023-00617-4","article-title":"Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimers disease","volume":"18","author":"Morrone","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.addr.2026.115808_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41556-024-01414-x","article-title":"Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington's disease","volume":"26","author":"Aviner","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41467-024-44732-2","article-title":"Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model","volume":"15","author":"Parfitt","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0095","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41586-021-04295-4","article-title":"Ageing exacerbates ribosome pausing to disrupt cotranslational proteostasis","volume":"601","author":"Stein","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrcardio.2017.89","article-title":"Proteostasis in cardiac health and disease","volume":"14","author":"Henning","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2026.115808_bb0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2019.01.034","article-title":"Endoplasmic reticulum proteostasis control and gastric cancer","volume":"449","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0110","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","article-title":"Deubiquitinases in cancer","volume":"23","author":"Dewson","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0120","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1038\/onc.2013.445","article-title":"Oncoprotein stabilization in brain tumors","volume":"33","author":"Hede","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115808_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0130","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0135","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0140","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115808_bb0150","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables-the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci. Bull."},{"key":"10.1016\/j.addr.2026.115808_bb0155","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/acs.jmedchem.2c01712","article-title":"Application of novel degraders employing autophagy for expediting medicinal research","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol"},{"key":"10.1016\/j.addr.2026.115808_bb0165","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115808_bb0170","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nchembio.1887","article-title":"Protein degradation: prime time for PROTACs","volume":"11","author":"Deshaies","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.addr.2026.115808_bb0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.scib.2023.04.028","article-title":"Stimuli-activatable PROTACs for precise protein degradation and cancer therapy","volume":"68","author":"Gao","year":"2023","journal-title":"Sci. Bull."},{"key":"10.1016\/j.addr.2026.115808_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113719","article-title":"Advancements in delivery systems for proteolysis-targeting chimeras (PROTACs): overcoming challenges and expanding biomedical applications","volume":"382","author":"Yu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115808_bb0195","article-title":"Unconventional PROTACs for targeted protein degradation in cancer therapy","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0200","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0205","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in pro-PROTAC development to address on-target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0210","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nn.4091","article-title":"Optogenetics: 10 years of microbial opsins in neuroscience","volume":"18","author":"Deisseroth","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2026.115808_bb0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nature11050","article-title":"Accelerated speciation in colour-polymorphic birds","volume":"485","author":"Hugall","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nature10360","article-title":"Neocortical excitation\/inhibition balance in information processing and social dysfunction","volume":"477","author":"Yizhar","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116041","article-title":"Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: from VHL ligands to VHL-based degraders","volume":"265","author":"Setia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0230","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0235","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115808_bb0240","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115808_bb0250","article-title":"Photoswitchable PROTACs for reversible and spatiotemporal regulation of NAMPT and NAD","volume":"63","author":"Cheng","year":"2024","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216258","article-title":"O-GlcNAcylation in cancer development and immunotherapy","volume":"566","author":"He","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cbpa.2019.09.001","article-title":"Molecular mechanisms regulating O-linked-acetylglucosamine (O-GlcNAc)-processing enzymes","volume":"53","author":"King","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0265","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nrm.2017.22","article-title":"Protein O-GlcNAcylation: emerging mechanisms and functions","volume":"18","author":"Yang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0270","doi-asserted-by":"crossref","first-page":"34672","DOI":"10.1021\/jacs.5c09843","article-title":"Enzyme-activated sugar-coated bifunctional degraders","volume":"147","author":"Zhu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0275","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","article-title":"Hallmarks of cellular senescence","volume":"28","author":"Hernandez-Segura","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0280","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1021\/jacs.7b04985","article-title":"An OFF-ON two-photon fluorescent probe for tracking cell senescence in vivo","volume":"139","author":"Lozano-Torres","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0285","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1002\/anie.202101278","article-title":"Two-dimensional design strategy to construct smart fluorescent probes for the precise tracking of senescence","volume":"60","author":"Gao","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0290","doi-asserted-by":"crossref","first-page":"17969","DOI":"10.1021\/acs.jmedchem.1c01313","article-title":"Noninvasive NIR imaging of senescence via in situ labeling","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0295","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s43587-021-00121-8","article-title":"Strategies for targeting senescent cells in human disease","volume":"1","author":"Gasek","year":"2021","journal-title":"Nat. Aging."},{"key":"10.1016\/j.addr.2026.115808_bb0300","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1002\/anie.201803321","article-title":"Macrotheranostic probe with disease-activated near-infrared fluorescence, photoacoustic, and photothermal signals for imaging-guided therapy","volume":"57","author":"Zhen","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s43587-023-00360-x","article-title":"Photoactivatable senolysis with single-cell resolution delays aging","volume":"3","author":"Shi","year":"2023","journal-title":"Nat. Aging."},{"key":"10.1016\/j.addr.2026.115808_bb0310","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1021\/acs.jmedchem.4c00152","article-title":"Selective elimination of senescent cancer cells by galacto-modified PROTACs","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0315","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2026.115808_bb0320","article-title":"A (211)at-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy","volume":"4","author":"Xie","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2026.115808_bb0325","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0330","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115808_bb0335","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","article-title":"Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer","volume":"46","author":"Yordanova","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.addr.2026.115808_bb0340","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/pros.23642","article-title":"Meeting report from the prostate cancer foundation PSMA-directed radionuclide scientific working group","volume":"78","author":"Miyahira","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.addr.2026.115808_bb0345","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1021\/jacs.4c18398","article-title":"A dual-targeted molecule for disease-activatable proteolysis targeting chimeras and targeted radionuclide therapy of cancer","volume":"147","author":"Zhang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0350","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrc4027","article-title":"Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response","volume":"15","author":"Olson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0355","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor alpha in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0360","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1002\/anie.201914826","article-title":"A fluorescent probe for rapid, high-contrast visualization of folate-receptor-expressing tumors in vivo","volume":"59","author":"Numasawa","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0365","doi-asserted-by":"crossref","first-page":"11657","DOI":"10.1021\/ja405372k","article-title":"Folate-based near-infrared fluorescent theranostic gemcitabine delivery","volume":"135","author":"Yang","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0370","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer selective target degradation by folate-caged PROTACs","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0375","doi-asserted-by":"crossref","first-page":"21546","DOI":"10.1002\/anie.202005612","article-title":"External-radiation-induced local hydroxylation enables remote release of functional molecules in tumors","volume":"59","author":"Fu","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0380","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/jacs.2c10177","article-title":"Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors","volume":"145","author":"Yang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nchembio.2024","article-title":"Development and application of bond cleavage reactions in bioorthogonal chemistry","volume":"12","author":"Li","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0390","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1039\/C8CS00395E","article-title":"Click and release: bioorthogonal approaches to \"on-demand\" activation of prodrugs","volume":"48","author":"Ji","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0395","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1021\/acs.chemrev.1c00469","article-title":"Introduction: click chemistry","volume":"121","author":"Devaraj","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0400","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1039\/C7CS00184C","article-title":"Inverse electron demand Diels-Alder reactions in chemical biology","volume":"46","author":"Oliveira","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0405","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1039\/c3cs60049a","article-title":"Inverse electron demand Diels-Alder (iEDDA)-initiated conjugation: a (high) potential click chemistry scheme","volume":"42","author":"Knall","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0410","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115808_bb0415","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2021.12.025","article-title":"Tumor-stroma TGF-\u03b21-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin \u03b1v\u03b23\/CD36-mediated activation of the MAPK pathway","volume":"528","author":"Nan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0420","doi-asserted-by":"crossref","first-page":"14155","DOI":"10.1021\/jacs.3c05159","article-title":"Bioorthogonal PROTAC prodrugs enabled by on-target activation","volume":"145","author":"Chang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0425","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1021\/acs.chemrev.0c00306","article-title":"Enzymatic noncovalent synthesis","volume":"120","author":"He","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0430","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1039\/C6CS00656F","article-title":"Bioinspired assembly of small molecules in cell milieu","volume":"46","author":"Wang","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0435","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1021\/jacs.7b11582","article-title":"Enzymatic cleavage of branched peptides for targeting mitochondria","volume":"140","author":"He","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0440","article-title":"Intrahippocampal supramolecular assemblies directed bioorthogonal liberation of neurotransmitters to suppress seizures in freely moving mice","volume":"36","author":"Wu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0445","doi-asserted-by":"crossref","first-page":"18208","DOI":"10.1021\/jacs.5c04857","article-title":"Reactive oxygen species-instructed supramolecular assemblies enable bioorthogonally activatable protein degradation for pancreatic cancer","volume":"147","author":"Yao","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao5902","article-title":"Chemically induced proximity in biology and medicine","volume":"359","author":"Stanton","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115808_bb0455","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0460","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0465","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115808_bb0470","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01560-z","article-title":"Tumour-specific bioorthogonal synthesis of proteolysis-targeting chimeras and nanoparticles boosts T cell activity","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0475","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1083\/jcb.201804161","article-title":"Glutathione metabolism in cancer progression and treatment resistance","volume":"217","author":"Bansal","year":"2018","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb0480","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217697","article-title":"Glutathione metabolism in ferroptosis and cancer therapy","volume":"621","author":"Xue","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0490","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1038\/s41467-024-53646-y","article-title":"Tumor-targeted glutathione oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121110","article-title":"Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy","volume":"277","author":"Niu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115808_bb0500","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115808_bb0505","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrmicro1458","article-title":"Aptamers come of age - at last","volume":"4","author":"Bunka","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2026.115808_bb0510","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115808_bb0515","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/jacs.9b10510","article-title":"Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer","volume":"142","author":"He","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0520","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41467-017-01565-6","article-title":"A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0525","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0530","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","article-title":"Emerging therapies in cancer metabolism","volume":"35","author":"Xiao","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.addr.2026.115808_bb0535","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2021.03.006","article-title":"Bioevaluation of glucose-modified liposomes as a potential drug delivery system for cancer treatment using 177-Lu radiotracking","volume":"332","author":"Cvjetinovic","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115808_bb0540","doi-asserted-by":"crossref","first-page":"12035","DOI":"10.1002\/anie.201606121","article-title":"Targeted delivery and sustained antitumor activity of triptolide through glucose conjugation","volume":"55","author":"He","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0545","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1021\/acs.jmedchem.5c00468","article-title":"GLUTs-facilitated targeting BRD4 degradation in breast cancer through carbohydrate-conjugated PROTACs","volume":"68","author":"Gao","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0550","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia--a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0555","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0560","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-022-01645-2","article-title":"The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies","volume":"21","author":"Bai","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0565","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115808_bb0570","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2014.01.032","article-title":"Hypoxia and hypoxia inducible factors in tumor metabolism","volume":"356","author":"Zeng","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0575","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1021\/jacs.6b06229","article-title":"Mitochondrial nitroreductase activity enables selective imaging and therapeutic targeting","volume":"138","author":"Chevalier","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0580","doi-asserted-by":"crossref","first-page":"15426","DOI":"10.1021\/acsami.9b04488","article-title":"Nitroreductase-activatable theranostic molecules with high PDT efficiency under mild hypoxia based on a TADF fluorescein derivative","volume":"11","author":"Liu","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115808_bb0585","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational design for nitroreductase (NTR)-responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0590","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0595","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1021\/jacs.2c12493","article-title":"Two color imaging of different hypoxia levels in cancer cells","author":"Wallabregue","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0600","doi-asserted-by":"crossref","first-page":"36352","DOI":"10.1021\/jacs.5c10240","article-title":"Indolequinone-based hypoxia-activated proteolysis targeting chimeras selectively degrade BRD4 in hypoxic cancer cells","volume":"147","author":"Serafini","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0605","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87705","article-title":"Searching for molecular hypoxia sensors among oxygen-dependent enzymes","volume":"12","author":"Li","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.addr.2026.115808_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117237","article-title":"Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands","volume":"82","author":"Cheng","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0615","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1021\/jacs.2c13732","article-title":"Enzyme-responsive double-locked photodynamic molecular beacon for targeted photodynamic anticancer therapy","volume":"145","author":"Tam","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0620","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41557-023-01242-w","article-title":"Near-infrared-activated anticancer platinum(IV) complexes directly photooxidize biomolecules in an oxygen-independent manner","volume":"15","author":"Deng","year":"2023","journal-title":"Nat. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0625","article-title":"Developing hypoxia-sensitive system via designing tumor-targeted fullerene-based photosensitizer for multimodal therapy of deep tumor","volume":"36","author":"Li","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0630","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1038\/s41467-024-54854-2","article-title":"MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition","volume":"15","author":"Tong","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0635","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1016\/j.apsb.2025.07.020","article-title":"Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors","volume":"15","author":"Fu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115808_bb0640","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41570-021-00277-2","article-title":"Dual-locked spectroscopic probes for sensing and therapy","volume":"5","author":"Wu","year":"2021","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb0645","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1039\/D2CS00889K","article-title":"Bioorthogonal chemistry for prodrug activation in vivo","volume":"52","author":"Fu","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0650","article-title":"Tandem-activatable PROTAC prodrug for tumor biomarker-driven near-infrared opto-proteolysis","volume":"64","author":"Lu","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0655","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1021\/jacs.5c00131","article-title":"Dual-action-only PROTACs","volume":"147","author":"Dutta","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0660","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq2216","article-title":"Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras","volume":"8","author":"Do","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115808_bb0665","article-title":"Enzyme-activated orthogonal proteolysis chimeras for tumor microenvironment-responsive immunomodulation","volume":"64","author":"Sun","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0670","article-title":"Stimuli-responsive PROTACs for controlled protein degradation","volume":"62","author":"An","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0675","article-title":"Nanoparticle-mediated targeted protein degradation: an emerging therapeutics technology","volume":"64","author":"Baker","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0680","article-title":"In vivo self-assembly of PROTACs by bioorthogonal chemistry for precision cancer therapy","volume":"64","author":"Xie","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0685","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41565-021-00910-7","article-title":"Bioorthogonal catalytic patch","volume":"16","author":"Chen","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115808_bb0690","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2023.07.062","article-title":"Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy","volume":"361","author":"Huang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115808_bb0695","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0700","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccr.2013.03.023","article-title":"Standing out from the crowd: cancer stem cells in hepatocellular carcinoma","volume":"23","author":"Sainz","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0705","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13608","article-title":"LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells","volume":"7","author":"Zhu","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0710","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1158\/0008-5472.CAN-21-2934","article-title":"Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma","volume":"82","author":"Mok","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115808_bb0715","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","article-title":"Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications","volume":"19","author":"Lee","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2026.115808_bb0720","article-title":"In situ tumor vaccination with nanoparticle co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response","volume":"33","author":"Ngamcherdtrakul","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0725","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0730","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202209379","article-title":"A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis","volume":"35","author":"Su","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0735","first-page":"4858","article-title":"Liposomal STAT3-degrading PROTAC prodrugs promote anti-hepatocellular carcinoma immunity via chemically reprogramming cancer stem cells","author":"Wang","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0740","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain","volume":"15","author":"Nord","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115808_bb0745","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"St\u00e5hl","year":"2017","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2026.115808_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.153437","article-title":"Amphiphilic affibody-PROTAC conjugate self-assembled nanoagents for targeted cancer therapy","volume":"495","author":"Gao","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.addr.2026.115808_bb0755","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1007\/s12274-024-6974-x","article-title":"A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2026.115808_bb0760","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0765","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","article-title":"Rational chemical design of molecular glue degraders","volume":"9","author":"Toriki","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.addr.2026.115808_bb0770","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/acscentsci.4c00286","article-title":"DCAF16-based covalent handle for the rational design of monovalent degraders","volume":"10","author":"Lim","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.addr.2026.115808_bb0775","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/jacs.4c11003","article-title":"A self-assembled nano-molecular glue (nano-mGlu) enables GSH\/H2O2-triggered targeted protein degradation in cancer therapy","volume":"147","author":"Sun","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0780","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103978","article-title":"Conquering the hypoxia limitation for photodynamic therapy","volume":"33","author":"Wan","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0785","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1039\/D0CS01370F","article-title":"Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies","volume":"50","author":"Xie","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0790","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1021\/jacs.3c04109","article-title":"Self-assembled nano-PROTAC enables near-infrared photodynamic proteolysis for cancer therapy","volume":"145","author":"Wang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb0795","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0800","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0805","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0810","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0815","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","article-title":"Heterogeneity in cancer: cancer stem cells versus clonal evolution","volume":"138","author":"Shackleton","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0820","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0825","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41565-020-00793-0","article-title":"A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells","volume":"16","author":"Shen","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115808_bb0830","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115808_bb0835","first-page":"21","article-title":"Hypoxia and hypoxia inducible factors in cancer stem cell maintenance","volume":"345","author":"Li","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.addr.2026.115808_bb0840","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2026.115808_bb0850","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41419-023-05788-y","article-title":"CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR\/PI3K pathway","volume":"14","author":"Mao","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115808_bb0855","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0860","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","article-title":"A luminal unfolding microneedle injector for oral delivery of macromolecules","volume":"25","author":"Abramson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115808_bb0865","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2017.08.009","article-title":"Device-assisted transdermal drug delivery","volume":"127","author":"Lee","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0870","article-title":"Silk microneedle patch capable of on-demand multidrug delivery to the brain for glioblastoma treatment","volume":"34","author":"Wang","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0875","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.matt.2021.11.017","article-title":"Immunomodulatory microneedle patch for periodontal tissue regeneration","volume":"5","author":"Zhang","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.addr.2026.115808_bb0880","article-title":"Self-oxygenating PROTAC microneedle for spatiotemporally-confined protein degradation and enhanced glioblastoma therapy","volume":"37","author":"Jiang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0885","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb0890","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115808_bb0895","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0900","article-title":"Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy","volume":"61","author":"Zhang","year":"2022","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb0905","article-title":"Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0910","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb0915","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0920","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-025-02405-6","article-title":"Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy","volume":"10","author":"Park","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115808_bb0925","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12951-022-01644-x","article-title":"Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity","volume":"20","author":"Shim","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115808_bb0930","article-title":"Light-triggered PROTAC nanoassemblies for photodynamic IDO proteolysis in cancer immunotherapy","volume":"36","author":"Choi","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0935","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1016\/j.apsb.2025.06.028","article-title":"Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy","volume":"15","author":"Jang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115808_bb0940","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2026.115808_bb0945","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115808_bb0950","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115808_bb0955","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115808_bb0960","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115808_bb0965","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115808_bb0970","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41467-019-09760-3","article-title":"Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice","volume":"10","author":"Yue","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb0975","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202302508","article-title":"Augmenting immunogenic cell death and alleviating myeloid-derived suppressor cells by sono-activatable semiconducting polymer nanopartners for immunotherapy","volume":"35","author":"Ding","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb0980","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115808_bb0985","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jama.2019.10232","article-title":"Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2026.115808_bb0990","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1021\/acs.nanolett.4c02287","article-title":"Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115808_bb0995","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115808_bb1000","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41571-022-00709-y","article-title":"Predicting tumour radiosensitivity to deliver precision radiotherapy","volume":"20","author":"Price","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb1005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","article-title":"Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers","volume":"17","author":"Buckley","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2026.115808_bb1010","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2\u20133, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2026.115808_bb1015","article-title":"X-ray-induced release of nitric oxide from hafnium-based nanoradiosensitizers for enhanced radio-immunotherapy","volume":"35","author":"Liu","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb1020","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/s41467-022-30787-6","article-title":"BRD4 promotes resection and homology-directed repair of DNA double-strand breaks","volume":"13","author":"Barrows","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb1025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41419-018-0789-1","article-title":"BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115808_bb1030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2017.01.031","article-title":"The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21","volume":"391","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115808_bb1035","article-title":"PROTAC prodrug-integrated nanosensitizer for potentiating radiation therapy of cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb1040","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115808_bb1045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115808_bb1050","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202203958","article-title":"Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy","volume":"34","author":"Zou","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb1055","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115808_bb1060","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","article-title":"MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas","volume":"11","author":"Oldrini","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb1065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1541-7786.MCR-16-0125","article-title":"Augmented HR repair mediates acquired temozolomide resistance in glioblastoma","volume":"14","author":"del Alcazar","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.addr.2026.115808_bb1070","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1541-7786.MCR-09-0299","article-title":"Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways","volume":"7","author":"Liu","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.addr.2026.115808_bb1075","article-title":"Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma","volume":"37","author":"Xu","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb1080","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70401","article-title":"Proteolysis-targeting chimera (PROTAC): current applications and future directions","volume":"6","author":"Fan","year":"2025","journal-title":"Medcomm"},{"key":"10.1016\/j.addr.2026.115808_bb1085","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1039\/D5CS00141B","article-title":"Intracellular aggregation of exogenous molecules for biomedical applications","volume":"54","author":"Hou","year":"2025","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb1090","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202411179","article-title":"Assembly-glued ligands and warheads for hypoxia-activatable supramolecular covalent inhibitors","volume":"34","author":"Hu","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb1095","doi-asserted-by":"crossref","first-page":"10753","DOI":"10.1021\/jacs.4c00826","article-title":"Sulfatase-induced in situ formulation of antineoplastic supra-PROTACs","volume":"146","author":"Chen","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb1100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115808_bb1105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and functional complexity of HSP90 in cellular homeostasis and disease","volume":"24","author":"Chiosis","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115808_bb1110","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1021\/acs.jmedchem.2c01970","article-title":"Design, synthesis, and biological evaluation of androgen receptor (AR) antagonist-heat shock protein 90 (Hsp90) inhibitor conjugates for targeted therapy of castration-resistant prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"PROTAC 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115808_bb1120","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1038\/s41467-023-40244-7","article-title":"DNA framework-engineered chimeras platform enables selectively targeted protein degradation","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115808_bb1125","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.1021\/jacs.2c12824","article-title":"Targeted biomolecule regulation platform: a split-and-mix PROTAC approach","volume":"145","author":"Yang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115808_bb1130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115808_bb1135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1126\/science.1205962","article-title":"Functional supramolecular polymers","volume":"335","author":"Aida","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115808_bb1140","doi-asserted-by":"crossref","first-page":"12576","DOI":"10.1039\/D0CS01571G","article-title":"Customized materials-assisted microorganisms in tumor therapeutics","volume":"50","author":"Chen","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb1145","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201904337","article-title":"Recent advances in nanostrategies capable of overcoming biological barriers for tumor management","volume":"32","author":"Huo","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115808_bb1150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein degradation by in-cell self-assembly of proteolysis targeting chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.addr.2026.115808_bb1155","article-title":"Nano proteolysis targeting chimeras (PROTACs) with anti-hook effect for tumor therapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115808_bb1160","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nchem.2852","article-title":"Engineering nucleic acid structures for programmable molecular circuitry and intracellular biocomputation","volume":"9","author":"Li","year":"2017","journal-title":"Nat. Chem."},{"key":"10.1016\/j.addr.2026.115808_bb1165","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1021\/acs.nanolett.4c00552","article-title":"Dynamic assembly of DNA nanostructures in cancer cells enables the coupling of autophagy activating and real-time tracking","volume":"24","author":"Guo","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115808_bb1170","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1021\/acs.chemrev.7b00663","article-title":"DNA nanotechnology-enabled drug delivery systems","volume":"119","author":"Hu","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb1175","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1021\/acs.accounts.9b00167","article-title":"Functional DNA molecules enable selective and stimuli-responsive nanoparticles for biomedical applications","volume":"52","author":"Li","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2026.115808_bb1180","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1039\/C7CS00055C","article-title":"Hybridization chain reaction: a versatile molecular tool for biosensing, bioimaging, and biomedicine","volume":"46","author":"Bi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb1185","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1039\/D1CS00240F","article-title":"Biosensing with DNAzymes","volume":"50","author":"McConnell","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115808_bb1190","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202306587","article-title":"Nucleic acid-to-small molecule converter through amplified hairpin DNA circuits","volume":"62","author":"Morihiro","year":"2023","journal-title":"Angew. Chem. Int. Edit."},{"key":"10.1016\/j.addr.2026.115808_bb1195","article-title":"MicroRNA-triggered programmable DNA-encoded pre-PROTACs for cell-selective and controlled protein degradation","volume":"64","author":"Zhan","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T08:32:15Z","timestamp":1779006735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":239,"alternative-id":["S0169409X26000426"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115808","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stimuli-activatable protein degraders for targeted cancer therapy: from prodrug design to nanoplatform applications","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115808"}}